Hanall Biopharma rises 7.68% amid COVID-19 (Dexamethasone) theme surge

On the 14th, the COVID-19 (Dexamethasone) theme rose by 3.14% compared to the previous day, showing strength, while HanAll Biopharma, a related stock attracting attention, surged by 7.68% compared to the previous day. HanAll Biopharma is known as an R&D-focused pharmaceutical and bio company.

[Graph] Major stock price changes in the COVID-19 (Dexamethasone) theme

According to provisional data compiled at 11:31, foreigners are net selling 5,100 shares of HanAll Biopharma, while institutions are net buying 28,000 shares.

[Table] Net trading volume of foreigners and institutions (unit: 10,000 shares)

[Table] Top stocks by financial score within the theme

※ The quant financial score is the result of a robo-algorithm analysis based on each company's sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, and other factors.

※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.